PRL-295

• Description :

  PRL-295 is an orally active inhibitor targeting Keap1-Nrf2 interaction. PRL-295 increases the thermal stability of Keap1 and disrupts its interaction with Nrf2, thereby activating the Nrf2-dependent transcriptional target NAD (P) H:quinone oxidoreductase 1 (NQO1) . PRL-295 protects against Acetaminophen (HY-66005) -induced liver injury in mice[1].

• CAS Number :

  [2377770-85-7]

• UNSPSC :

  12352005

• Target :

  Aminotransferases (Transaminases) ; Keap1-Nrf2; Quinone Reductase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease; NF-κB

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/prl-295.html

• Smiles :

  O=C(CN(S(=O)(C1=CC=C(C=C1)OC)=O)C2=NC=C(N(S(=O)(C3=CC=C(C=C3)OC)=O)CC(F)(F)F)C4=C2C=CC=C4)O

• Molecular Formula :

  C27H24F3N3O8S2

• Molecular Weight :

  639.62

• References & Citations :

  [1]Dayalan Naidu S, et al. The isoquinoline PRL-295 increases the thermostability of Keap1 and disrupts its interaction with Nrf2. iScience. 2021 Dec 27, 25 (1) :103703.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported